SCHEMBL22012670

SCHEMBL22012670

CC(C)(C)OC(=O)NCCCn1cc(O)cn1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.47
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
STK17B O94768 1/20 0.44
STK17A Q9UEE5 1/20 0.44
DRD2 P14416 5/20 0.44
ALDH1A1 P00352 2/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
GFER P55789 1/20 0.41
CYP3A4 P08684 1/20 0.41
MIF P14174 1/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
MALT1 Q9UDY8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22366404 0.88 TDP1 (0.46) TDP1MEN1GAAKMT2ASTK17B
SCHEMBL19027486 0.87 DRD2 (0.45) TDP1MEN1GAAKMT2ASTK17B
SCHEMBL31627058 0.87 TDP1 (0.44) TDP1MEN1GAAKMT2ASTK17B
SCHEMBL16245608 0.87 TDP1 (0.44) TDP1MEN1GAAKMT2ASTK17B
SCHEMBL20140741 0.86 L3MBTL1 (0.52) TDP1MEN1GAAKMT2ASTK17B
SCHEMBL13165704 0.86 MEN1 (0.45) TDP1MEN1GAAKMT2ASTK17B
SCHEMBL23513095 0.85 TDP1 (0.43) TDP1MEN1GAAKMT2ASTK17B
SCHEMBL16199411 0.84 MEN1 (0.43) TDP1MEN1GAAKMT2ASTK17B
SCHEMBL16245563 0.83 TDP1 (0.47) TDP1MEN1GAAKMT2ASTK17B
SCHEMBL29800785 0.83 TDP1 (0.47) TDP1MEN1GAAKMT2ASTK17B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112771040-B Monocyclic lactam compounds and uses thereof 南京圣和药业股份有限公司 2022-10-18 CN disclosed
US-20220002288-A1 MONOBACTAM COMPOUNDS AND USE THEREFOR NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2022-01-06 US disclosed
EP-3882246-A1 MONOBACTAM COMPOUNDS AND USE THEREFOR Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) 2021-09-22 EP disclosed
WO-2020098635-A1 MONOBACTAM COMPOUNDS AND USE THEREFOR 南京圣和药业股份有限公司 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002288-A1 MONOBACTAM COMPOUNDS AND USE THEREFOR BPGM, IL1B, WEE1 TDP1 3885/4885MEN1 707/4885GAA 1883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.